Literature DB >> 30798765

Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies.

Hanny Al-Samkari.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30798765     DOI： 10.1177/0194599818813521

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN： 0194-5998            Impact factor:   3.497


× No keyword cloud information.
  4 in total

1.  Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement.

Authors:  Zain M Virk; Andrew B Song; Yousef R Badran; Hanny Al-Samkari
Journal:  J Thromb Thrombolysis       Date:  2022-07-13       Impact factor: 5.221

2.  Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.

Authors:  Hanny Al-Samkari; Hasan A Albitar; Scott E Olitsky; Marianne S Clancy; Vivek N Iyer
Journal:  Orphanet J Rare Dis       Date:  2019-11-14       Impact factor: 4.123

3.  A Rare Case of Upper Gastrointestinal Bleeding: Osler-Weber-Rendu Syndrome.

Authors:  Anna Jargielo; Anna Rycyk; Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  Medicina (Kaunas)       Date:  2022-02-22       Impact factor: 2.430

4.  An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.

Authors:  Hanny Al-Samkari; Raj S Kasthuri; Joseph G Parambil; Hasan A Albitar; Yahya A Almodallal; Carolina Vázquez; Marcelo M Serra; Sophie Dupuis-Girod; Craig B Wilsen; Justin P McWilliams; Evan H Fountain; James R Gossage; Clifford R Weiss; Muhammad A Latif; Assaf Issachar; Meir Mei-Zahav; Mary E Meek; Miles Conrad; Josanna Rodriguez-Lopez; David J Kuter; Vivek N Iyer
Journal:  Haematologica       Date:  2021-08-01       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.